Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Angelo Carotti"'
Publikováno v:
Methods in Molecular Biology ISBN: 9781071626429
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21b0e41d3ba68389e060ca5ede8f4722
https://doi.org/10.1007/978-1-0716-2643-6_15
https://doi.org/10.1007/978-1-0716-2643-6_15
Autor:
Michele Tonelli, Marco Catto, Raimon Sabaté, Valeria Francesconi, Erik Laurini, Sabrina Pricl, Leonardo Pisani, Daniela Valeria Miniero, Grazia Maria Liuzzi, Elena Gatta, Annalisa Relini, Rosalina Gavín, Jose Antonio Del Rio, Fabio Sparatore, Angelo Carotti
Publikováno v:
European Journal of Medicinal Chemistry. 250:115169
A set of twenty-five thioxanthene-9-one and xanthene-9-one derivatives, that were previously shown to inhibit cholinesterases (ChEs) and amyloid β (Aβ40) aggregation, were evaluated for the inhibition of tau protein aggregation. All compounds exhib
Autor:
Rolf W. Hartmann, Chris J. van Koppen, Matthias W. Laschke, Giuseppe Felice Mangiatordi, Ahmed S. Abdelsamie, Martin Frotscher, Orazio Nicolotti, Abdelrahman Mohamed, Angelo Carotti, Arcangela Mazzini, Hanna Drzewiecka, Emanuele M. Gargano, Paweł P. Jagodziński, Sandrine Marchais-Oberwinkler
Publikováno v:
ACS medicinal chemistry letters
United States
ACS Med Chem Lett
ACS medicinal chemistry letters (2021). doi:10.1021/acsmedchemlett.1c00462
info:cnr-pdr/source/autori:Emanuele M. Gargano, Abdelrahman Mohamed, Ahmed S. Abdelsamie, Giuseppe F. Mangiatordi, Hanna Drzewiecka, Pawe? P. Jagodzi?ski, Arcangela Mazzini, Chris J. van Koppen, Matthias W. Laschke, Orazio Nicolotti, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, and Martin Frotscher/titolo:17?-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer/doi:10.1021%2Facsmedchemlett.1c00462/rivista:ACS medicinal chemistry letters/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume
United States
ACS Med Chem Lett
ACS medicinal chemistry letters (2021). doi:10.1021/acsmedchemlett.1c00462
info:cnr-pdr/source/autori:Emanuele M. Gargano, Abdelrahman Mohamed, Ahmed S. Abdelsamie, Giuseppe F. Mangiatordi, Hanna Drzewiecka, Pawe? P. Jagodzi?ski, Arcangela Mazzini, Chris J. van Koppen, Matthias W. Laschke, Orazio Nicolotti, Angelo Carotti, Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, and Martin Frotscher/titolo:17?-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer/doi:10.1021%2Facsmedchemlett.1c00462/rivista:ACS medicinal chemistry letters/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume
[Image: see text] In the face of the clinical challenge posed by non-small cell lung cancer (NSCLC), the present need for new therapeutic approaches is genuine. Up to now, no proof existed that 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b72b1eb9a0d3948ea61df325c6e341e
https://hdl.handle.net/10033/623149
https://hdl.handle.net/10033/623149
Autor:
Emanuele M Gargano, Giuseppe Allegretta, Enrico Perspicace, Angelo Carotti, Chris Van Koppen, Martin Frotscher, Sandrine Marchais-Oberwinkler, Rolf W Hartmann
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0134754 (2015)
Design and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracel
Externí odkaz:
https://doaj.org/article/0bc4d2b54c854517a63ff00bf9fcb5c9
Publikováno v:
ARKIVOC, Vol 2004, Iss 5, Pp 272-285 (2004)
Externí odkaz:
https://doaj.org/article/9cb72061c1d3484cac83601d8e23daf6
Autor:
Leonardo Pisani, Roberta Farina, Ramon Soto-Otero, Nunzio Denora, Giuseppe Felice Mangiatordi, Orazio Nicolotti, Estefania Mendez-Alvarez, Cosimo Damiano Altomare, Marco Catto, Angelo Carotti
Publikováno v:
Molecules, Vol 21, Iss 3, p 362 (2016)
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particularly Alzheimer’s disease (AD), shifted research towards reliable drug discovery strategies to unveil clinical candidates with higher therapeutic effic
Externí odkaz:
https://doaj.org/article/c09f9e97369d4be098250e548664a9f5
Autor:
Beáta Flachner, Zsolt Lörincz, Angelo Carotti, Orazio Nicolotti, Praveena Kuchipudi, Nikita Remez, Ferran Sanz, József Tóvári, Miklós J Szabó, Béla Bertók, Sándor Cseh, Jordi Mestres, György Dormán
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e35582 (2012)
A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity screening on tumor HCT116 and no
Externí odkaz:
https://doaj.org/article/3723a4fc6cdc46bd98dc182350806210
Autor:
Ilenia Giangreco, Gianluca Lattanzi, Orazio Nicolotti, Marco Catto, Antonio Laghezza, Francesco Leonetti, Angela Stefanachi, Angelo Carotti
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25597 (2011)
Matrix metalloproteinases (MMP) are well-known biological targets implicated in tumour progression, homeostatic regulation, innate immunity, impaired delivery of pro-apoptotic ligands, and the release and cleavage of cell-surface receptors. Hence, th
Externí odkaz:
https://doaj.org/article/0dd6ff74dd1241729dc69a686197f111
Autor:
Dimitra Hadjipavlou-Litina, Aikaterini Peperidou, Angelo Carotti, Konstantinos E. Litinas, Michael G. Kallitsakis, Marco Catto
Publikováno v:
The Open Medicinal Chemistry Journal
Introduction: The 1,3-dipolar cycloaddition reactions of nitrile oxides formed in situ (in the presence of NCS and Et3N) from the oximes of (purin-9-yl)acetaldehyde or (coumarinyloxy)acetaldehyde with allyloxycoumarins or 9-allylpurines, respectively
Autor:
Odra Pinato, Marco Catto, Fausta Palluotto, Barbara Gatto, Angelo Carotti, Alice Sosic, Grigoris Zoidis, Claudia Sissi
Publikováno v:
European Journal of Medicinal Chemistry. 123:704-717
The quinoline motif fused with other heterocyclic systems plays an important role in the field of anticancer drug development. An extensive series of tetracyclic quinolino[3,4-b]quinoxalines N-5 or C-6 substituted with basic side chain and a limited